CI

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Cigna Group stock has delivered a 44.4% gain over the past five years, yet the broader valuation checks still suggest the shares screen as undervalued at the recent price of US$277.51. With shorter term returns weaker, investors are left weighing a mixed share price history against a still supportive valuation read. Over five years, Cigna Group has returned 44.4%, which points to solid long term wealth creation despite more recent share price softness. Expectations for the company to keep generating dependable cash flows from its health insurance and related services can support the current valuation. At the same time, any pressure on medical cost trends or pricing power may limit how much investors are willing to pay for that cash flow stream. Cigna Group screens as undervalued on the broader checks, with the company passing 6 of 6 valuation tests, which leans in favor of the stock being priced below what those metrics suggest is reasonable. The issue now is whether that high value score and longer term return justify taking the recent share price weakness as an opportunity or a warning sign on Cigna Group. Find out why Cigna Group's -6.8% return over the last year is lagging behind its peers. The P/E ratio is a useful way to look at Cigna Group because earnings are a key driver for how investors typically assess large health insurers. On this measure, Cigna Group trades on a P/E of about 11.4x, which is well below the wider Healthcare sector average of roughly 25.5x and the peer group average near 31.6x. The tailored fair P/E ratio for Cigna Group is estimated at about 28.7x, which is more than double the current multiple. That gap suggests the stock is pricing in a much lower earnings valuation than what the fair ratio implies based on the company’s profile and risk factors. Investors watching Cigna Group may see this as a sign that the market is applying a cautious earnings multiple compared with both sector benchmarks and this model’s fair value yardstick. Overall, the P/E comparison indicates that Cigna Group stock appears undervalued on this earnings multiple. See what the numbers say about this price — find out in our valuation breakdown. Simply Wall St Narratives for Cigna Group pick up where this valuation puzzle leaves off and spell out what would need to happen to growth, margins and earnings for the stock to be worth materially more or less than today’s price. Each narrative presents Cigna Group's fair value as a thesis about the business that you can revisit over time, and they are available on the company’s Community page for investors who want that extra layer of structure. You can share your own narrative on Cigna Group's growth, margins and execution and set out a clear, number-driven case that others in the community can follow over time. Add your voice to the Simply Wall St community and see how your thesis tracks as new results arrive. Do you think there's more to the story for Cigna Group? Head over to our Community to see what others are saying! Cigna Group screens as undervalued on earnings compared with both its sector and peer averages, which leaves the debate centered on why the market is keeping the P/E multiple this low. The key question is whether concerns around medical cost trends and pricing power prove persistent enough to justify that discount. If those pressures remain contained, a re rating of the multiple becomes the crux of the upside case. If they intensify, the current valuation may simply reflect a market that is correctly cautious rather than mispricing Cigna Group stock. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CI. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

CVS Health CVS is entering the second half of 2026 with stronger earnings momentum, higher cash generation and an improved Aetna profit outlook. Those gains strengthen the recovery case after a difficult period for the insurer. The trade-off is that medical-cost pressure and changing pharmacy benefit manager economics remain unresolved. CVS trades below major valuation benchmarks, but its multiple is already above its own five-year median. The Zacks Consensus Estimate for 2026 earnings has increased 7.9% over the prior four weeks, while projected 2026 EPS growth stands at 16.6%. Current cash flow growth of 65.3% adds another positive signal. Second-quarter results support that trend. Adjusted EPS increased 42.5% year over year to $2.58, while adjusted operating income rose 35.4% to $5.16 billion. CVS also raised 2026 adjusted EPS guidance to $7.90-$8.10. Image Source: Zacks Investment Research CVS trades at 11.7X forward 12-month earnings, below the Zacks sub-industry's 16.2X and the S&P 500's 20.8X. The gap shows that investors still assign CVS a sizable discount despite improving earnings. Image Source: Zacks Investment Research The stock is less cheap against its own history. CVS' five-year median forward multiple is 10.3X, below the current level. Relative valuation is favorable, but the shares are not unusually inexpensive compared with their historical norm. Health Care Benefits is the clearest operating reason for greater confidence. Adjusted operating income increased by more than $2 billion year over year in the first half of 2026 as pricing discipline and medical-cost management improved profitability. CVS raised the segment's 2026 adjusted operating income outlook to $5.03-$5.37 billion, more than $1 billion above prior guidance. The medical benefit ratio improved to 87.4% in the second quarter from 89.9% a year earlier, showing measurable progress in the margin-recovery plan. The recovery still faces pressure from elevated medical utilization and reimbursement changes. CVS continues to take a prudent view of second-half medical costs, while retail pharmacy and pharmacy services face reimbursement and client-pricing pressure. Caremark adds uncertainty. Weaker 340B conditions are expected to create a 2027 earnings headwind, while management anticipates lower pharmacy benefit manager membership next year. Specialty pharmacy and generic opportunities may offset part of that pressure, but uneven earnings remain possible. The Cigna Group CI is relevant because its Evernorth Health Services business includes pharmacy benefit and related health-service operations. Cigna therefore offers another diversified model exposed to benefit-management economics. UnitedHealth Group UNH combines a large insurance franchise with health-services operations through Optum. It provides another useful reference point for investors assessing medical-cost and health-services trends across managed care. The bottom line is that CVS has better earnings momentum and a favorable relative valuation, but execution risk remains. Aetna is improving, while medical utilization, reimbursement pressure and Caremark's 2027 reset argue for more evidence that the gains can persist. CVS currently carries a Zacks Rank #3 (Hold), which fits that mixed setup rather than signaling an aggressive entry point. The stock also has a Value Score of A, Growth Score of A, Momentum Score of A and VGM Score of A. Those scores indicate favorable characteristics across several styles, but they are designed to complement the Zacks Rank. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CVS Health Corporation (CVS) : Free Stock Analysis Report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Cigna Group (CI) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Let’s dig into the relative performance of Cigna (NYSE:CI) and its peers as we unravel the now-completed Q2 health insurance providers earnings season. Upfront premiums collected by health insurers lead to reliable revenue, but profitability ultimately depends on accurate risk assessments and the ability to control medical costs. Health insurers are also highly sensitive to regulatory changes and economic conditions such as unemployment. Going forward, the industry faces tailwinds from an aging population, increasing demand for personalized healthcare services, and advancements in data analytics to improve cost management. However, continued regulatory scrutiny on pricing practices, the potential for government-led reforms such as expanded public healthcare options, and inflation in medical costs could add volatility to margins. One big debate among investors is the long-term impact of AI and whether it will help underwriting, fraud detection, and claims processing or whether it may wade into ethical grey areas like reinforcing biases and widening disparities in medical care. The 12 health insurance providers stocks we track reported a strong Q2. As a group, revenues beat analysts’ consensus estimates by 2.8% while next quarter’s revenue guidance was 1.7% below. While some health insurance providers stocks have fared somewhat better than others, they have collectively declined. On average, share prices are down 3.1% since the latest earnings results. With roots dating back to 1792 and serving millions of customers across the globe, The Cigna Group (NYSE:CI) provides healthcare services through its Evernorth Health Services and Cigna Healthcare segments, offering pharmacy benefits, specialty care, and medical plans. Cigna reported revenues of $71.56 billion, up 6.6% year on year. This print exceeded analysts’ expectations by 1.2%. Overall, it was a satisfactory quarter for the company with a beat of analysts’ EPS estimates. Even though it had a relatively good quarter, the market seems discontent with the results. The stock is down 4.8% since reporting and currently trades at $282.28. Is now the time to buy Cigna? Access our full analysis of the earnings results here, it’s free. With over 9,000 retail pharmacy locations serving as neighborhood health destinations across America, CVS Health (NYSE:CVS) operates retail pharmacies, provides pharmacy benefit management services, and offers health insurance through its Aetna subsidiary. CVS Health reported revenues of $106.1 billion, up 7.3% year on year, outperforming analysts’ expectations by 6.7%. The business had an incredible quarter with a beat of analysts’ EPS estimates and a solid beat of analysts’ full-year EPS guidance estimates. Although it had a fine quarter compared to its peers, the market seems unhappy with the results as the stock is down 7% since reporting. It currently trades at $97.16. Is now the time to buy CVS Health? Access our full analysis of the earnings results here, it’s free. Pioneering a data-driven approach to family building that has achieved an industry-leading patient satisfaction score of +80, Progyny (NASDAQ:PGNY) provides comprehensive fertility and family building benefits solutions to employers, helping employees access quality fertility treatments and support services. Progyny reported revenues of $350.5 million, up 5.3% year on year, exceeding analysts’ expectations by 0.6%. Still, it was a slower quarter as it posted EBITDA guidance for next quarter missing analysts’ expectations significantly and full-year revenue guidance slightly missing analysts’ expectations. Progyny delivered the weakest guidance update in the group. As expected, the stock is down 13% since the results and currently trades at $26.29. Read our full analysis of Progyny’s results here. Founded in 2014 to improve healthcare for America's seniors through technology, Clover Health (NASDAQ:CLOV) provides Medicare Advantage plans for seniors with a focus on affordable care and uses its proprietary Clover Assistant software to help physicians manage patient care. Clover Health reported revenues of $743.2 million, up 55.6% year on year. This number beat analysts’ expectations by 2%. It was an exceptional quarter as it also produced a beat of analysts’ EPS estimates and full-year EBITDA guidance exceeding analysts’ expectations. The company added 1,536 customers to reach a total of 157,309. The stock is up 10.6% since reporting and currently trades at $4.58. Read our full, actionable report on Clover Health here, it’s free. Founded in 1980 as a provider for underserved communities in Southern California, Molina Healthcare (NYSE:MOH) provides managed healthcare services primarily to low-income individuals through Medicaid, Medicare, and Marketplace insurance programs across 21 states. Molina Healthcare reported revenues of $10.87 billion, down 4.8% year on year. This result was in line with analysts’ expectations. Zooming out, it was a slower quarter as it recorded full-year revenue guidance missing analysts’ expectations significantly. Molina Healthcare had the weakest performance against analyst estimates, slowest revenue growth, and weakest full-year guidance update among its peers. The company lost 108,000 customers and ended up with a total of 4.93 million. The stock is down 4.1% since reporting and currently trades at $212.75. Read our full, actionable report on Molina Healthcare here, it’s free. Over the past year, investors have been forced to repeatedly answer the same question: what is the market’s biggest risk? The answer has changed several times, and each shift has reshaped market leadership. Late in 2025 and early 2026, artificial intelligence became the market’s primary uncertainty. Investors questioned whether AI would erode software pricing power and weaken competitive moats as AI made it easier to replicate once-differentiated products. By the spring, technology took a back seat to geopolitics. The U.S. conflict with Iran briefly became the market’s dominant narrative, raising concerns about oil prices, inflation, and global growth. But as energy markets remained orderly and fears of a prolonged supply disruption faded, investors quickly turned their focus back to fundamentals. Want to invest in winners with rock-solid fundamentals? Check out our Hidden Gem Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.

CVS Health CVS raised its 2026 earnings and cash-flow outlook after a second quarter marked by stronger profitability across all operating segments. The improvement gives the company more room to rebuild margins after a difficult period for its Aetna insurance business. The recovery is gaining traction, but the path is not risk-free. Medical-cost pressure, reimbursement changes and a changing pharmacy benefit manager environment could still test the durability of the higher outlook. Second-quarter adjusted earnings rose 42.5% year over year to $2.58 per share, while revenues increased 7.3% to $106.10 billion. Adjusted operating income advanced 35.4% to $5.16 billion, reflecting gains across all operating segments. Health Care Benefits delivered the largest earnings improvement, while Health Services and Pharmacy & Consumer Wellness also posted higher adjusted operating income. That broader contribution matters because the recovery is not resting on a single business line. CVS lifted its 2026 adjusted EPS guidance to $7.90-$8.10 from $7.30-$7.50. The company now expects consolidated revenues of at least $414 billion and adjusted operating income of $16.58-$16.92 billion. Here’s where consensus estimates for the company’s revenues and earnings currently stand. Image Source: Zacks Investment Research Expected cash flow from operations also rose to at least $11.5 billion from at least $9.5 billion. The stronger cash outlook supports further leverage improvement after the company ended the second quarter with a leverage ratio of about 3.5 times. Aetna's Health Care Benefits business is becoming a larger earnings contributor as pricing discipline and medical-cost management improve results. Second-quarter adjusted operating income reached $2.43 billion, up 85.5% year over year, while the medical benefit ratio improved to 87.4% from 89.9%. CVS raised the segment's 2026 adjusted operating income outlook to $5.03-$5.37 billion, more than $1 billion above its prior guidance. Management expects the full-year medical benefit ratio to be about 89.75%, plus or minus 25 basis points, while continuing to take a prudent view of second-half medical costs. The higher outlook does not remove execution risk. CVS expects the Health Care Benefits medical benefit ratio to rise materially through the second half, while reimbursement pressure continues in retail pharmacy and pharmacy services. Weakness in the 340B business is also expected to create a 2027 headwind. Caremark faces another transition as regulatory changes and the shift toward net-cost pricing reshape pharmacy benefit manager economics. Management also expects lower Caremark membership in 2027 as it takes a more disciplined approach to contract renewals and some health-plan clients exit products or markets. Peer results show that managed-care and pharmacy-services operators are also adjusting to changing cost and contracting conditions. UnitedHealth Group UNH raised its 2026 adjusted earnings outlook after its second quarter, while The Cigna Group CI increased its 2026 adjusted income outlook after reporting year-over-year revenue and earnings growth. CVS has clearer operating momentum than it did a year ago, led by Aetna's margin recovery, stronger pharmacy execution and higher cash generation. Still, the second-half medical-cost trajectory and 2027 pharmacy-services headwinds argue for a measured view rather than assuming the recovery is complete. The stock currently carries a Zacks Rank #3 (Hold). CVS also has a Value Score of A, Growth Score of A, Momentum Score of A and VGM Score of A. Those favorable Style Scores point to attractive characteristics across valuation, growth and momentum, but the Zacks Rank keeps the near-term signal balanced as investors assess whether the higher guidance can translate into sustained. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CVS Health Corporation (CVS) : Free Stock Analysis Report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Cigna Group (CI) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Cigna Group (CI) is back on investors’ radar after reporting its second quarter 2026 results, alongside an update on a long running share repurchase program dating back to 2018. See our latest analysis for Cigna Group. Cigna Group’s latest earnings and long running buyback program have come alongside mixed share price momentum. The stock is up 2.63% on the day and has a modest 1.21% share price return year to date, while the 5 year total shareholder return of 47.06% reflects a stronger longer term outcome. If this healthcare update has you thinking about where else growth and efficiency could meet, it may be worth scanning 43 healthcare AI stocks for other potential ideas in the sector. With Cigna Group shares only modestly ahead this year after fresh earnings and a long running buyback, the question now is whether to treat the recent uptick as a workable entry point or to wait for a cheaper setup. Cigna Group closed at $282.49 compared to a narrative fair value of $340.92, which frames the stock as materially undervalued on that view. Read the complete narrative. Want to see what this potential specialty pharmacy tailwind means for Cigna Group's earnings path and profit multiple assumptions? The full narrative unpacks how expected revenue trends, margin shifts and share count changes all connect to that $340.92 fair value and the implied discount rate story. Result: Fair Value of $340.92 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, you also need to weigh Cigna Group’s heavy reliance on the Evernorth PBM model and ongoing regulatory scrutiny, which could pressure margins and future contract wins. Find out about the key risks to this Cigna Group narrative. With both risks and rewards in play for Cigna Group, it makes sense to review the numbers yourself and decide quickly where you stand. To see a concise summary of the key concerns alongside the potential upsides that investors are watching, start with 6 key rewards and 1 important warning sign. If Cigna Group has sharpened your focus on quality, now is the moment to widen your search and line up a few fresh ideas before the next move. Spot potential mispricings early and compare them with your watchlist using the 51 high quality undervalued stocks. Strengthen your income stream by reviewing companies that feature in the 8 dividend fortresses. Reduce portfolio stress and focus on resilience by exploring the 79 resilient stocks with low risk scores. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CI. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

Investing.com -- Jefferies downgraded Cigna to Hold from Buy, arguing that a growing list of earnings headwinds and limited catalysts outweigh the stock's discounted valuation, while cutting its price target to $307 from $336. The brokerage said consensus earnings expectations for 2027 remain too optimistic, citing uncertainty surrounding the strategic review of EviCore and the health insurance exchange (HIX) business, increasing pressure from reduced GLP-1 drug coverage, and mounting regulatory scrutiny of pharmacy benefit managers (PBMs). It lowered its 2027 earnings estimate to $32.77 per share, about 1% below consensus. Jefferies said a potential sale or wind-down of EviCore and the HIX business could create a meaningful earnings gap. It estimates EviCore contributes $700 million to $1 billion in adjusted operating income, or $2.20-$3.10 per share, and warned that share buybacks would not fully offset the earnings dilution from a divestiture. Combined with stranded costs from exiting the HIX business, these factors could reduce 2027 adjusted operating income by roughly 10% versus current consensus expectations. The brokerage also expects pressure from weight-loss GLP-1 drugs to intensify next year. After management disclosed a $20 million-per-quarter headwind beginning in the second half of 2026, Jefferies estimates further reductions in employer coverage could increase the 2027 earnings impact to about $126 million, weighing on the profitability of the company's pharmacy benefit services business. Beyond GLP-1s, Jefferies highlighted risks from declining membership at key pharmacy benefit clients, including Medicaid, health insurance exchange and Medicare Part D plans, as well as a wave of state-level legislation targeting PBM pricing, transparency and ownership structures. The firm said these changes could cap margin expansion and create a longer-term overhang for the PBM business model. While Jefferies acknowledged the stock trades at a depressed valuation of roughly 8.3 times consensus 2027 earnings, it said the discount is warranted given weaker growth prospects, limited catalysts for multiple expansion and ongoing execution risks as the company transitions to a rebate-free PBM model. Related articles Jefferies downgrades Cigna to Hold on mounting 2027 earnings headwinds Nvidia's new Alpamayo project: What it means for Tesla? 5 reasons why Jefferies thinks Meta’s pullback is a buying opportunity

The Cigna Group recently reported past second-quarter 2026 results showing higher sales of US$67.03 billion, revenue of US$71.67 billion, and net income of US$1.66 billion, alongside increased earnings per share from continuing operations versus a year earlier. Alongside raising its full-year adjusted earnings outlook, Cigna continued capital returns through share repurchases and affirmed a quarterly dividend of US$1.56 per share, while pressing ahead with its rebate-free Signature pharmacy benefit model and plans to exit the ACA exchange after 2026. We’ll now examine how Cigna’s stronger-than-expected second-quarter earnings and higher full-year outlook influence the existing investment narrative. Outshine the giants: these 16 early-stage AI stocks could fund your retirement. To own Cigna, you need to be comfortable with a diversified health services business that leans heavily on Evernorth, specialty pharmacy and employer-focused insurance, while managing regulatory and affordability pressures. The stronger than expected second quarter results and higher full year earnings outlook support the near term catalyst around expanding health services, although they do not remove the key risk that evolving PBM regulation and pricing scrutiny could pressure margins and reshape parts of the business model. Within the latest news, the raised full year adjusted earnings outlook to at least US$30.45 per share stands out as most relevant, because it ties directly to Cigna’s ability to monetize growth in Evernorth and Cigna Healthcare while reinvesting in models such as the rebate free Signature PBM. For investors focused on the health services catalyst, this updated guidance provides an anchor for assessing how operational execution tracks against the evolving regulatory and affordability risks ahead. Yet despite the strong quarter, investors should still be watching how tighter PBM rules and pricing transparency initiatives could affect Evernorth’s margins and long term earnings power... Read the full narrative on Cigna Group (it's free!) Cigna Group's narrative projects $315.1 billion revenue and $7.8 billion earnings by 2029. This requires 4.3% yearly revenue growth and about a $1.5 billion earnings increase from $6.3 billion today. Uncover how Cigna Group's forecasts yield a $340.92 fair value, a 19% upside to its current price. Nine fair value estimates from the Simply Wall St Community span roughly US$310 to over US$920 per share, showing how far apart individual views can be. When you set that against Cigna’s reliance on Evernorth and the PBM model under growing regulatory scrutiny, it becomes clear why checking several viewpoints can be useful before forming your own expectations for the business. Explore 9 other fair value estimates on Cigna Group - why the stock might be worth over 3x more than the current price! Don't just follow the ticker - dig into the data and build a conviction that's truly your own. A great starting point for your Cigna Group research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision. Our free Cigna Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cigna Group's overall financial health at a glance. Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay: Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource. Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution. This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CI. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

Interested in Cigna Group? Here are five stocks we like better. Cigna raised its 2026 adjusted EPS outlook to at least $30.45 after second-quarter revenue reached $71.7 billion and adjusted EPS came in at $7.78, exceeding management’s expectations across Evernorth and Cigna Healthcare. Evernorth’s Specialty and Care Services delivered strong growth, with pretax adjusted earnings up 22% year over year, offsetting weaker Pharmacy Benefit Services results amid investments in the rebate-free Signature model and shifting drug economics. Cigna Healthcare also outperformed, prompting the company to raise its full-year segment earnings outlook to at least $4.55 billion. Cigna plans to launch Signature in fully insured plans in 2027, exit the ACA exchange business after 2026, and continue investing in AI-enabled pharmacy and care-coordination tools. UnitedHealth Just Gave Wall Street a Clearer Turnaround Signal Cigna Group (NYSE:CI) raised its full-year 2026 adjusted earnings outlook after reporting second-quarter results that management said exceeded expectations in both its Evernorth health services business and Cigna Healthcare insurance segment. The company reported second-quarter total revenue of $71.7 billion, adjusted after-tax earnings of $2.1 billion and adjusted earnings per share of $7.78. Cigna also recorded after-tax special-item charges of $153 million, or $0.58 per share, during the quarter. → Why SK hynix Could Be the Best AI Chip Stock to Buy Now The AI Boom Has a Second Act—And It's Playing Out in Optics For the full year, Cigna increased its adjusted earnings-per-share outlook to at least $30.45. CFO Ann Dennison said the guidance reflects strong first-half performance while retaining what she described as a “prudent view” of the operating environment. Evernorth Health Services generated $61.5 billion in second-quarter revenue, up 6% from a year earlier, and $1.7 billion in pretax adjusted earnings. Its Specialty and Care Services unit produced $1.1 billion in pretax adjusted earnings, a 22% year-over-year increase that exceeded management’s expectations. → Microsoft Just Flipped the AI Spending Narrative Overnight Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum Dennison attributed the performance to continued specialty-drug utilization growth, quicker-than-anticipated adoption of biosimilars and specialty generics, operating efficiencies and income from Cigna’s investment in Shields Health Solutions. She said specialty-generic penetration for newer products exceeded 80% in the quarter. The company said increased biosimilar and specialty-generic adoption improves affordability for clients and patients, but it also shifts earnings within Evernorth. Dennison said the dynamic boosts Specialty and Care Services while reducing contributions from Pharmacy Benefit Services, in part because lower drug costs affect revenue and the economics of the pharmacy-benefits business. → Carrier Earnings Could Send the Stock to a New All-Time High Pharmacy Benefit Services reported pretax adjusted earnings of $609 million, down from the prior year and broadly in line with expectations. Management cited the impact of previously discussed extensions and renewals of large client contracts, as well as investment spending tied to the transition to its rebate-free pharmacy-benefits model, Signature. Cigna said it expects full-year Evernorth pretax adjusted earnings of at least $6.9 billion. While specialty generics and biosimilars should remain a meaningful tailwind, Dennison said the magnitude of the second-quarter benefit is not expected to recur at the same level in the third and fourth quarters. Management also cited moderating GLP-1 prescription growth. Coverage levels declined slightly and utilization growth slowed from the elevated levels in earlier periods, a trend the company expects to continue through the rest of 2026. CEO Brian Evanko said the anticipated modest pressure from lower GLP-1 volumes in the second half is expected to effectively offset Evernorth’s second-quarter outperformance. Cigna Healthcare posted second-quarter revenue of $11.8 billion, up 10% year over year, and pretax adjusted earnings of $1.3 billion. The segment’s medical care ratio was 84.5%, slightly better than the company expected. Management said the segment benefited from strong performance in its U.S. employer business and medical-cost trends that were slightly favorable to expectations. The company pointed to lower outpatient trends, including lower surgical spending, while noting that overall medical-cost trends remained elevated but stable at high-single-digit levels. Cigna raised its full-year pretax adjusted earnings outlook for Cigna Healthcare to at least $4.55 billion. It expects more than 60% of second-half segment earnings to occur in the third quarter and expects the third-quarter medical care ratio to be slightly above the second-quarter level, consistent with historical seasonality. Evanko said the company continues to see growth in medical membership in the employer market and cited disciplined pricing, care coordination and stop-loss margin recapture as contributors to performance. Dennison said stop-loss results tracked in line with expectations and were not a driver of second-quarter variance. On independent dispute resolution, or IDR, claims, Evanko said Cigna supports consumer protections against surprise medical billing but sees “clear abuses” in the mechanism. He said the company views the impact as manageable within its Cigna Healthcare planning and pricing assumptions. Cigna plans to introduce Signature to Cigna Healthcare’s fully insured plans in 2027 before a broader market rollout in 2028. The company said the model is designed around fee-based arrangements, price transparency and a “Price Assure” capability intended to provide customers with the lowest available out-of-pocket cost. Evanko said Evernorth Pharmacy Benefit Services completed its 2026 selling season with retention above 97%, while preliminary indicators point to retention in the mid-90% range or higher for 2027. He said new business already secured for 2027 exceeds the prior two selling seasons combined. Management said it is tracking in line with expected Signature-related investment levels for 2026 and expects similar spending in 2027, with investment levels expected to decline over time. Evanko said the company expects Signature margins ultimately to be in the 4% range, similar to margins from legacy pharmacy-benefit solutions. Cigna expects approximately $9 billion in operating cash flow for 2026, weighted toward the second half. The company repurchased about 900,000 shares for approximately $250 million in the second quarter. Its debt-to-capitalization ratio was 42.8% as of June 30, and management expects to end the year closer to its 40% target. The company also highlighted artificial-intelligence initiatives in specialty pharmacy and care coordination. Evanko said its Pharmacy Forward program is expected to reduce average time to therapy by half and reduce clinician documentation time by up to 50%. Cigna also expanded AI-enabled care coordination intended to identify customers with emerging complex conditions earlier; management said the effort could extend support to 20% more customers. Evanko said customers who engage in the company’s care-coordination programs reduce medical costs by approximately $2,000 annually on average, while early engagement has been associated with a 42% reduction in avoidable inpatient stays among participating customers. Separately, Cigna plans to exit the ACA exchange business at the end of 2026. Management said the business is tracking in line with expectations for positive but below-target margins this year. Dennison said the exit may create some stranded overhead and produce only a modest capital release. Cigna Group (NYSE: CI) is a global health services company that offers a broad portfolio of healthcare products and insurance solutions for individuals, employers, and governments. Its core businesses include medical and behavioral health plans, dental and vision coverage, pharmacy benefit management, and supplemental health products. Cigna serves a mix of commercial, Medicare, and Medicaid customers and provides workplace benefits such as group health plans and disability and life benefits for employers. In addition to traditional insurance products, Cigna operates health services and care-delivery platforms designed to manage costs and improve outcomes. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Cigna Group Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for July 2026.